DAX23.630 -1,5%ESt505.326 -1,8%Top 10 Crypto14,67 +0,8%Dow41.603 -0,6%Nas18.737 -1,0%Bitcoin95.186 +0,4%Euro1,1367 ±0,0%Öl65,03 +1,6%Gold3.360 ±0,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 RENK RENK73 Apple 865985 Tesla A1CX3T D-Wave Quantum A3DSV9 Siemens Energy ENER6Y BYD A0M4W9 Deutsche Bank 514000 Lufthansa 823212 BASF BASF11 Mercedes-Benz Group (ex Daimler) 710000 EVOTEC 566480 Bayer BAY001 Infineon 623100
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Börsen gehen mit Verlusten ins Wochenende -- DAX geht weit unter 24.000er-Marke ins Wochenende -- IonQ und D-Wave im Blick -- Meta, Apple, Reddit, Amazon, Rheinmetall im Fokus
Top News
Portfolio angepasst: Auf diese Aktien setzte Carl Icahn im 1. Quartal 2025 Portfolio angepasst: Auf diese Aktien setzte Carl Icahn im 1. Quartal 2025
KW 21: So performten die MDAX-Aktien in der vergangenen Woche KW 21: So performten die MDAX-Aktien in der vergangenen Woche
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Reisekreditkarten im Vergleich: Das sind die beliebtesten Modelle
25 € Neukunden­bonus + 1 Aktie gratis. Hol Dir jetzt Dein finanzen.net ZERO-Depot!

Ardelyx Aktie

NeuKaufenVerkaufen
Ardelyx Aktien-Sparplan
3,49 EUR -0,01 EUR -0,20 %
STU
3,98 USD +0,02 USD +0,51 %
nachbörslich
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.835,61 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA116X0

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS0396971071

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolARDX

Ardelyx Aktien News

DatumMeistgelesen
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX
PR NewswireARDX Investors Have Opportunity to Lead Ardelyx, Inc.Securities Fraud Lawsuit with the Schall Law Firm
Wer­bungArdelyx-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireShareholders of Ardelyx, Inc. Should Contact The Gross Law Firm Before October 15, 2024 to Discuss Your Rights - ARDX
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadlines - ARDX
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadlines - ARDX
PR NewswireARDX Investors Have Opportunity to Lead Ardelyx, Inc.Securities Fraud Lawsuit with the Schall Law Firm
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadlines - ARDX
PR NewswireARDX Investors Have Opportunity to Lead Ardelyx, Inc.Securities Fraud Lawsuit with the Schall Law Firm
PR NewswireSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx
PR NewswireLevi & Korsinsky Reminds Ardelyx, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 15, 2024 - ARDX
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadlines - ARDX
PR NewswireSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx
PR NewswireARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadlines - ARDX
PR NewswireARDX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ardelyx, Inc. Investors Can Join the Class Action Lawsuit!
PR NewswireArdelyx, Inc. Reports Employment Inducement Grants
PR NewswireFDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor)
PR NewswireArdelyx, Inc. Reports Employment Inducement Grants
PR NewswireArdelyx Provides Update on FDA Appeal for XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
PR NewswireArdelyx to Present at the 34th Annual Piper Sandler Healthcare Conference
PR NewswireArdelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dia...
PR NewswireArdelyx Stock Trading Halted Today; FDA Advisory Committee to Discuss XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
PR NewswireNational Kidney Foundation and Ardelyx, Inc. Survey Finds Dialysis Patients Struggle to Maintain Serum Phosphorus Levels
PR NewswireArdelyx Reports Third Quarter 2022 Financial Results and Recent Business Highlights
PR NewswireArdelyx Presents New Data Analyses at Kidney Week 2022, Further Supporting the Clinical Relevance of XPHOZAH® (tenapanor), an Investigational, Phosphate Absorption Inhibitor to Control Serum Phosp...
PR NewswireArdelyx, Inc. Reports Employment Inducement Grants
PR NewswireArdelyx Collaboration Partner, Kyowa Kirin, Announces Submission of New Drug Application for Tenapanor for Hyperphosphatemia in Japan
PR NewswireArdelyx to Report Third Quarter 2022 Financial Results on November 3, 2022
PR NewswireArdelyx to Present Poster Presentations on IBSRELA® (tenapanor) for Adult Patients with IBS-C at the American College of Gastroenterology 2022 Annual Scientific Meeting
PR NewswireArdelyx Announces Poster Presentations on XPHOZAH® (tenapanor) at ASN's Kidney Week 2022
PR NewswireArdelyx to Participate in Upcoming Investor Conferences
PR NewswireArdelyx Reports Second Quarter 2022 Financial Results and Recent Business Highlights
PR NewswireArdelyx to Present at the 2022 Wedbush PacGrow Healthcare Conference
PR NewswireArdelyx to Report Second Quarter 2022 Financial Results on August 4, 2022
PR NewswireArdelyx, Inc. Reports Employment Inducement Grants
PR NewswireArdelyx Announces $20 Million Financing Agreement with HealthCare Royalty Partners
PR NewswireArdelyx Announces FDA Advisory Committee Meeting to Review XPHOZAH® NDA Tentatively Scheduled for November 16, 2022
PR NewswireArdelyx to Present at the Jefferies 2022 Healthcare Conference
Wer­bung

Ardelyx News

Ardelyx News: auf dieser Seite finden Sie alle Ardelyx News und Nachrichten zur Ardelyx Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Ardelyx News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Ardelyx News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.